NEW ORAL DRUGSNovartis press release: "Phase II data for FTY720 shows sustained efficacy and good tolerability over 18 months in patients with relapsing MS"
"The data, presented at the American Association of Neurology (AAN) meeting, showed that both patient groups taking FTY720 (1.25 mg and 5 mg) who had experienced more than a 50% reduction in their annualized relapse2 rate during the study's first six months compared to placebo maintained this low relapse rate during the subsequent 12-month extension.

Currently marketed MS therapies afford an average reduction in relapse rates of only 30% in two-year studies and require frequent injections ranging from daily to weekly 3,4,5,6......"